| [1] |
DANON MJ, OH SJ, DIMAURO S, et al. Lysosomal glycogen storage disease with normal acid maltase[J]. Neurology, 1981, 31(1): 51-57. DOI: 10.1212/wnl.31.1.51. |
| [2] |
NISHINO I, FU J, TANJI K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease)[J]. Nature, 2000, 406(6798): 906-910. DOI: 10.1038/35022604. |
| [3] |
CHI C, RICHING AS, SONG K. Lysosomal abnormalities in cardiovascular disease[J]. Int J Mol Sci, 2020, 21(3): 811. DOI: 10.3390/ijms21030811. |
| [4] |
CHI C, LEONARD A, KNIGHT WE, et al. LAMP-2B regulates human cardiomyocyte function by mediating autophagosome-lysosome fusion[J]. Proc Natl Acad Sci U S A, 2019, 116(2): 556-565. DOI: 10.1073/pnas.1808618116. |
| [5] |
CENACCHI G, PAPA V, PEGORARO V, et al. Review: Danon disease: Review of natural history and recent advances[J]. Neuropathol Appl Neurobiol, 2020, 46(4): 303-322. DOI: 10.1111/nan.12587. |
| [6] |
CHARRON P, VILLARD E, SÉBILLON P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey[J]. Heart, 2004, 90(8): 842-846. DOI: 10.1136/hrt.2003.029504. |
| [7] |
FU L, LUO S, CAI S, et al. Identification of LAMP2 mutations in early-onset danon disease with hypertrophic cardiomyopathy by targeted next-generation sequencing[J]. Am J Cardiol, 2016, 118(6): 888-894. DOI: 10.1016/j.amjcard.2016.06.037. |
| [8] |
GUO S, ZHOU L, WANG R, et al. Danon disease: Two patients with atrial fibrillation in a single family and review of the literature[J]. Exp Ther Med, 2019, 18(3): 1527-1532. DOI: 10.3892/etm.2019.7777. |
| [9] |
CHEN X, FU L, HE J, et al. A frequent observation of wolff-parkinson-white syndrome and fasciculoventricular pathways in patients with danon disease[J]. Circ J, 2022, 86(2): 309-318. DOI: 10.1253/circj.CJ-21-0572. |
| [10] |
SUGIE K, YAMAMOTO A, MURAYAMA K, et al. Clinicopathological features of genetically confirmed Danon disease[J]. Neurology, 2002, 58(12): 1773-1778. DOI: 10.1212/wnl.58.12.1773. |
| [11] |
ZHANG Y, REN H, ZHOU S. A case report of delayed diagnosis of danon disease: Caused by a newly recognized mutation in the lysosome-associated membrane protein-2 gene[J]. Medicine (Baltimore), 2020, 99(40): e22640. DOI: 10.1097/MD.0000000000022640. |
| [12] |
|
| [13] |
D'SOUZA RS, LEVANDOWSKI C, SLAVOV D, et al. Danon disease: clinical features, evaluation, and management[J]. Circ Heart Fail, 2014, 7(5): 843-849. DOI: 10.1161/CIRCHEARTFAILURE.114.001105. |
| [14] |
GURKA J, PIHEROVA L, MAJER F, et al. Danon disease is an underdiagnosed cause of advanced heart failure in young female patients: a LAMP2 flow cytometric study[J]. ESC Heart Fail, 2020, 7(5): 2534-2543. DOI: 10.1002/ehf2.12823. |
| [15] |
MANSO AM, HASHEM SI, NELSON BC, et al. Systemic AAV9. LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease[J]. Sci Transl Med, 2020, 12(535). DOI: 10.1126/scitranslmed.aax1744. |
| [16] |
XUE R, FAN JG. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007. |
| [17] |
LEE SB, PARK GM, LEE JY, et al. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study[J]. J Hepatol, 2018, 68(5): 1018-1024. DOI: 10.1016/j.jhep.2017.12.012. |
DownLoad:
